---
title: "CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290475313.md"
description: "In Boston on June 22, 2026, CervoMed Inc. (NASDAQ: CRVO), a biotech company focusing on age-related brain disorders, revealed the completion of a registered direct offering under Nasdaq rules. The offering involved the sale and purchase of 2,500,000 common stock shares at $4.00 per share. This move marks a significant step for CervoMed in its clinical-stage development of treatments for age-related brain conditions."
datetime: "2026-06-22T20:07:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290475313.md)
  - [en](https://longbridge.com/en/news/290475313.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290475313.md)
generator: "portal-rs"
---

# CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

In Boston on June 22, 2026, CervoMed Inc. (NASDAQ: CRVO), a biotech company focusing on age-related brain disorders, revealed the completion of a registered direct offering under Nasdaq rules. The offering involved the sale and purchase of 2,500,000 common stock shares at $4.00 per share. This move marks a significant step for CervoMed in its clinical-stage development of treatments for age-related brain conditions.

### Related Stocks

- [CRVO.US](https://longbridge.com/en/quote/CRVO.US.md)

## Related News & Research

- [CervoMed neflamapimod Phase 2a nfvPPA biomarker data set for ISFTD 2026 oral session](https://longbridge.com/en/news/298589195.md)
- [CervoMed management joins Cantor Global Healthcare Conference fireside chat](https://longbridge.com/en/news/298311086.md)
- [Tyra Biosciences reports 79% response rate in Phase 2 bladder cancer study of dabogratinib at 60 mg dose](https://longbridge.com/en/news/298445177.md)
- [VRTX: Upcoming renal and pain launches, pivotal data, and global expansion drive growth outlook](https://longbridge.com/en/news/298508921.md)
- [TENX: Levosimendan benefits PH-HFpEF patients with high disease burden, guiding a refined LEVEL-2 trial](https://longbridge.com/en/news/298456291.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**